Back to search

Article

CYP3A5 inhibition causes G1/S blockade and synergizes with CDK4/6 inhibitor to suppress prostate cancer cell growth: Implications in reducing health disparity

2024-10-03

Abstract excerpt

Prostate cancer (PC) is a leading cause of death in men because of the high incidence and long-term inefficacy of the existing treatment options. Furthermore, it exhibits significant health disparities that affect African-American (AA) men more adversely than others do. Previously, we established CYP3A5, a highly expressed protein in AAs PC, as a positive regulator of androgen receptor (AR) signaling. We examined...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
858e88b0-dd18-54da-bf39-21e0f1742873
DOI
10.1101/2024.10.01.616176
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
CYP3A5 inhibition causes G1/S blockade and synergizes with CDK4/6 inhibitor to suppress prostate cancer cell growth: Implications in reducing health disparityDOI 10.1101/2024.10.01.616176
Role of CYP3A5 in modulating androgen receptor signaling and its relevance to African American men with prostate cancerSemantic proximity
Integrative genomic and bioinformatic prioritization of drug repurposing candidates for prostate cancer.Semantic proximity
Clofazimine treatment modulates key non-coding RNAs associated with tumor progression and drug resistance in lethal Prostate CancerSemantic proximity
Targeting CDK9: a promising therapeutic opportunity in prostate cancerSemantic proximity
APOBEC3B-driven mutations negatively regulated by P53 promote tumor progression and immunosuppressive microenvironment in prostate cancer.Semantic proximity
A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer.Semantic proximity
Metabolic CRISPR screening identifies RPE as a key regulator of acquired enzalutamide resistance through FKBP5 destabilization in prostate cancer.Semantic proximity
Role of solute carrier transporters SLC25A17 and SLC27A6 in acquired resistance to enzalutamide in castration‐resistant prostate cancerSemantic proximity
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancerSemantic proximity
Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 – 2014)Semantic proximity
The Roles of Drug Metabolism-Related ADH1B in Immune Regulation and Therapeutic Response of Ovarian CancerSemantic proximity
Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7Semantic proximity
Select a neighboring publication to make it the new centre.